Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Fallopian Tube Neoplasms 4Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Primary Myelofibrosis 2Neoplasms 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Glioblastoma 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1

Interventions

tremelimumab 2fludarabine 2durvalumab 2aflibercept 2Trastuzumab 2Radiotherapy 2Radiosurgery 2Cyclophosphamide 2Cisplatin 2tipifarnib 1sapropterin 1oncogene protein E7, Human papillomavirus type 16 1entinostat 1Vaccines 1Topotecan 1Therapeutics 1Radiation 1Platinum 1Pharmacogenomic Testing 1Papillomavirus Vaccines 1Nelfinavir 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gemcitabine 1Ganciclovir 1E6 protein, Human papillomavirus type 16 1Docetaxel 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Vulvar Neoplasms × Disulfides × Clear all
NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

M.D. Anderson Cancer Center

Phase 1 Completed
20 enrolled
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡